JPH0581589B2 - - Google Patents
Info
- Publication number
- JPH0581589B2 JPH0581589B2 JP27658587A JP27658587A JPH0581589B2 JP H0581589 B2 JPH0581589 B2 JP H0581589B2 JP 27658587 A JP27658587 A JP 27658587A JP 27658587 A JP27658587 A JP 27658587A JP H0581589 B2 JPH0581589 B2 JP H0581589B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- pyridine
- formula
- room temperature
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- -1 amide compound Chemical class 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 42
- 150000001875 compounds Chemical class 0.000 description 28
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 239000013078 crystal Substances 0.000 description 12
- 238000000921 elemental analysis Methods 0.000 description 12
- 238000002844 melting Methods 0.000 description 12
- 230000008018 melting Effects 0.000 description 12
- 230000000704 physical effect Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000010446 mirabilite Substances 0.000 description 6
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000003266 anti-allergic effect Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- IPFIEHIRBSTAKA-UHFFFAOYSA-N 6-piperidin-1-ylpyrimidine-2,4-diamine Chemical compound NC1=NC(N)=CC(N2CCCCC2)=N1 IPFIEHIRBSTAKA-UHFFFAOYSA-N 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IAGROJPXACRRDT-UHFFFAOYSA-N 2-piperidin-1-ylpyrimidine Chemical compound C1CCCCN1C1=NC=CC=N1 IAGROJPXACRRDT-UHFFFAOYSA-N 0.000 description 2
- YBIYFJLLJFMDFQ-UHFFFAOYSA-N 4-piperidin-1-ylpyrimidine Chemical compound C1CCCCN1C1=CC=NC=N1 YBIYFJLLJFMDFQ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- HZDNNJABYXNPPV-UHFFFAOYSA-N (2-chloro-2-oxoethyl) acetate Chemical compound CC(=O)OCC(Cl)=O HZDNNJABYXNPPV-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- NZHGWWWHIYHZNX-UHFFFAOYSA-N 2-((3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1C=CC(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-UHFFFAOYSA-N 0.000 description 1
- OZJZCCMIOZPPIT-UHFFFAOYSA-N 2-(2-methoxyethoxy)acetyl chloride Chemical compound COCCOCC(Cl)=O OZJZCCMIOZPPIT-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- ZPMWWAIBJJFPPQ-UHFFFAOYSA-N 2-ethoxyacetyl chloride Chemical compound CCOCC(Cl)=O ZPMWWAIBJJFPPQ-UHFFFAOYSA-N 0.000 description 1
- YLZYSVYZMDJYOT-UHFFFAOYSA-N 2-methoxypyrimidine Chemical compound COC1=NC=CC=N1 YLZYSVYZMDJYOT-UHFFFAOYSA-N 0.000 description 1
- VGUWZCUCNQXGBU-UHFFFAOYSA-N 3-[(4-methylpiperazin-1-yl)methyl]-5-nitro-1h-indole Chemical compound C1CN(C)CCN1CC1=CNC2=CC=C([N+]([O-])=O)C=C12 VGUWZCUCNQXGBU-UHFFFAOYSA-N 0.000 description 1
- DUIMWXDLDBNUFD-UHFFFAOYSA-N 4-pyrimidin-2-ylmorpholine Chemical compound C1COCCN1C1=NC=CC=N1 DUIMWXDLDBNUFD-UHFFFAOYSA-N 0.000 description 1
- QJIUMVUZDYPQRT-UHFFFAOYSA-N 6-chloro-2,4-pyrimidinediamine Chemical compound NC1=CC(Cl)=NC(N)=N1 QJIUMVUZDYPQRT-UHFFFAOYSA-N 0.000 description 1
- OSBMJXWHJWWZJP-UHFFFAOYSA-N 6-methoxypyrimidine-2,4-diamine Chemical compound COC1=CC(N)=NC(N)=N1 OSBMJXWHJWWZJP-UHFFFAOYSA-N 0.000 description 1
- DFSFIKNJVGWSMU-UHFFFAOYSA-N 6-morpholin-4-ylpyrimidine-2,4-diamine Chemical compound NC1=NC(N)=CC(N2CCOCC2)=N1 DFSFIKNJVGWSMU-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- VHNQIURBCCNWDN-UHFFFAOYSA-N pyridine-2,6-diamine Chemical compound NC1=CC=CC(N)=N1 VHNQIURBCCNWDN-UHFFFAOYSA-N 0.000 description 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(産業上の利用分野)
本発明は優れた抗アレルギー作用を有し、抗ア
レルギー剤として有用な新規なアミド化合物に関
する。
(従来の技術)
従来より各種アレルギー症状の予防、治療剤の
研究、開発が行なわれており、多くの化合物が報
告されている。抗アレルギー作用を有するアミド
化合物としては、例えばザ・ジヤーナル・オブ・
アレルギー・アンド・クリニカル・イムノロジー
(The Journal of Allergy and Clinical
Immunology)、57巻(No.5)、396頁(1976年)
にトラニラスト[N−(3,4−ジメトキシシン
ナモイル)アントラニル酸]が、またエージエン
ツ・アンド・アクシヨンズ(Agents And
Actions)、1巻、235頁(1979年)にロドキサマ
イドエチル[N,N′−(2−クロロ−5−シアノ
−m−フエニレン)ジオキサミン酸ジエチルエス
テル]が記載されている。
(発明が解決しようとする問題点)
従来の抗アレルギー剤は各種アレルギー症状、
特に気管支喘息の治療に十分な効果を示している
とは言い難い。
(問題点を解決するための手段)
本発明者らはアレルギー症状に対して優れた抗
アレルギー作用を示す薬物を得るべく種々の化合
物を合成し、その薬理作用を検討した結果、特定
のアミド化合物が抗アレルギー活性に優れている
ことを知り、本発明を完成するに至つた。
すなわち、本発明の化合物は式:
(Industrial Application Field) The present invention relates to a novel amide compound that has an excellent antiallergic effect and is useful as an antiallergic agent. (Prior Art) Research and development of preventive and therapeutic agents for various allergic symptoms have been carried out, and many compounds have been reported. As an amide compound with antiallergic effect, for example, The Journal of
The Journal of Allergy and Clinical
Immunology), Volume 57 (No. 5), Page 396 (1976)
tranilast [N-(3,4-dimethoxycinnamoyl)anthranilic acid], and Agents And Actions.
Actions), Vol. 1, p. 235 (1979) describes rhodoxamide ethyl [N,N'-(2-chloro-5-cyano-m-phenylene)dioxamic acid diethyl ester]. (Problems to be solved by the invention) Conventional anti-allergic agents can be used to treat various allergic symptoms,
In particular, it cannot be said that it has shown sufficient efficacy in the treatment of bronchial asthma. (Means for Solving the Problems) The present inventors synthesized various compounds in order to obtain drugs that exhibit excellent antiallergic effects against allergic symptoms, and as a result of examining their pharmacological effects, a specific amide compound The present invention was completed based on the discovery that the compound has excellent anti-allergic activity. That is, the compounds of the present invention have the formula:
【化】
[式中、R1は水素原子、低級アルキル基、ア
セチル基またはアルコキシアルキル基;R2は水
素原子、塩素原子、フエニル基、低級アルコキシ
基、または[Formula, R 1 is a hydrogen atom, a lower alkyl group, an acetyl group, or an alkoxyalkyl group; R 2 is a hydrogen atom, a chlorine atom, a phenyl group, a lower alkoxy group, or
【式】(R3およびR4は炭素
数1〜3のアルキレン基、Wは酸素原子またはメ
チレン基)で示される基;X,YおよびZは全て
が同時にCH−であることはなく、それぞれ窒
素原子又はCH−を示す。]で示されるアミド
化合物である。
本発明の式()の化合物において、R1にお
ける低級アルキル基としては炭素数1〜6個のア
ルキル基、好ましくはメチル基およびエチル基な
ど、アルコキシアルキル基としてはメトキシエチ
ル基などが挙げられる。R2における低級アルコ
キシ基としては炭素数1〜6個のアルコキシ基、
好ましくはメトキシ基などが挙げられる。
(製造方法)
本発明の化合物は()式:[Formula] (R 3 and R 4 are alkylene groups having 1 to 3 carbon atoms, W is an oxygen atom or methylene group); X, Y and Z are not all CH- at the same time, and each Indicates a nitrogen atom or CH-. ] It is an amide compound shown by. In the compound of formula () of the present invention, examples of the lower alkyl group in R 1 include an alkyl group having 1 to 6 carbon atoms, preferably a methyl group and an ethyl group, and examples of the alkoxyalkyl group include a methoxyethyl group. The lower alkoxy group in R 2 is an alkoxy group having 1 to 6 carbon atoms,
Preferred examples include methoxy group. (Production method) The compound of the present invention has the formula ():
【化】
[式中、R2は水素原子、塩素原子、フエニル
基、低級アルコキシ基または[In the formula, R 2 is a hydrogen atom, a chlorine atom, a phenyl group, a lower alkoxy group, or
【式】(R3
およびR4は炭素数1〜3のアルキレン基、Wは
酸素原子またはメチレン基)で示される基;(X,
YおよびZは全てが同時に、CH−であること
はなく、それぞれ窒素原子又はCH−を示す。
ジアミノ化合物を()式:[Formula] (R 3 and R 4 are alkylene groups having 1 to 3 carbon atoms, W is an oxygen atom or a methylene group); (X,
Y and Z are not all CH- at the same time, and each represents a nitrogen atom or CH-. Diamino compound () formula:
【化】
[式中、R1は低級アルキル基、アセチル基ま
たはアルコキシアルキル基]で示される酸塩化物
と反応させることにより製造される。
反応はピリジン等の非プロトン性溶媒中で実施
される。反応は外部からの熱の適用なしに起きる
が、反応完結を確実にするため、加熱してもよ
い。
R1がアセチル基である式()の化合物は加
水分解によりR1が水素原子である式()の化
合物に変換することができる。
(発明の効果)
本発明の化合物は即時型アレルギー反応を強力
に抑制する作用を有するので、即時型アレルギー
に分類される気管支喘息、じん麻疹、アレルギー
性鼻炎などの予防および治療に対して有用であ
る。
本発明化合物の抗アレルギー作用は以下に述べ
る試験例により確認された。
試験例
抗卵白アルブミンラツト血清をWistar系ラツ
ト(雄、体重約200g)の背部正中線の両側に
各々0.1ml宛、2点づつ計4点に皮内注射して受
動的に感作した。48時間後、卵白アルブミンおよ
びエバンスブルー混液1mlを尾静脈より投与して
PCA(受動皮膚アナフイラキシー)反応を惹起し
た。30分後、青染部を切り取り漏出色素量を
Katayamaらの方法[Microbiol.Immunol.,22
巻、89頁(1978年)]に従い測定した。
PCA反応惹起30分前に被験化合物を6匹のラ
ツトに30mg/Kgづつ経口投与した。第1表に本発
明化合物のPCA反応抑制率を示す。It is produced by reacting with an acid chloride represented by [Formula, R 1 is a lower alkyl group, acetyl group, or an alkoxyalkyl group]. The reaction is carried out in an aprotic solvent such as pyridine. The reaction occurs without external application of heat, but heating may be applied to ensure completion of the reaction. A compound of formula () in which R 1 is an acetyl group can be converted by hydrolysis into a compound of formula () in which R 1 is a hydrogen atom. (Effects of the Invention) The compounds of the present invention have the effect of strongly suppressing immediate allergic reactions, and therefore are useful for the prevention and treatment of bronchial asthma, hives, allergic rhinitis, etc., which are classified as immediate allergic reactions. be. The antiallergic effect of the compound of the present invention was confirmed by the test examples described below. Test Example Anti-ovalbumin rat serum was intradermally injected into Wistar rats (male, weighing approximately 200 g) at 0.1 ml each on both sides of the dorsal midline at 2 points each for a total of 4 points to passively sensitize them. After 48 hours, 1 ml of ovalbumin and Evans blue mixture was administered through the tail vein.
PCA (passive cutaneous anaphylaxis) reaction was induced. After 30 minutes, cut out the blue dyed area and measure the amount of leaked dye.
Katayama et al.'s method [Microbiol. Immunol., 22
Vol., p. 89 (1978)]. The test compound was orally administered to six rats at a dose of 30 mg/Kg 30 minutes before the induction of the PCA reaction. Table 1 shows the PCA reaction inhibition rate of the compounds of the present invention.
【表】【table】
【表】
本発明の化合物は、経口、非経口又は吸引によ
り投与されるが、経口投与が好ましい。また使用
に際しては通常の医薬担体を用いて常法により各
種製剤形に調製される。例えば、経口投与用には
錠剤、カプセル剤、顆粒剤、シロツプ剤、粉剤な
どが挙げられる。非経口投与用には静脈内注射の
ための水溶液、筋肉内注射のための油状懸濁液な
どが挙げられる。
またエアゾルスプレー、あるいは乾燥粉末の形
で本発明の化合物と肺が直接接触できるようにす
る吸引器によつて投与することもできる。本発明
の化合物の1日あたりの全投与量は2〜2000mgで
ある。
次に実施例を挙げて本発明を更に具体的に説明
するが、本発明はこれらに限定されない。
実施例 1
2,4−ビス(メトキシアセチルアミノ)−6
−ピペリジノ−ピリミジンの製造:
2,4−ジアミノ−6−ピペリジノピリミジン
5.0gをピリジン100mlに溶かした溶液に、室温で
塩化メトキシアセチル5mlを滴下した。その後、
浴温60℃で1時間、室温で終夜攪拌した。反応混
合物よりピリジンを減圧溜去して得られた固体に
水を加え懸濁させ、白色結晶を濾取し、これを水
で洗浄することにより、次の物理的性質を有する
表記化合物6.27gを得た。
融点:159〜160℃
IR(KBr):ν=3450,3260,2930,1725,
1685,1625,1575,1520,1440,1395,1340,
1315,1285,1260,1240,1220,1205,1135,
985,940,800cm-1
NMR(DMSO−d6):δ=9.55(1H,s),9.48
(1H,s),7.05(1H,s),4.20(2H,s),4.05
(2H,s),3.53(4H,br.s),3.35(3H,s),
3.32(3H,s),1.60(6H,br.s)
元素分析値
計算値:C,53.40;H,6.87;
N,20.76(%)
実測値:C,53.46;H,6.72;
N,20.81(%)
実施例 2
2,4−ビス(メトキシアセチルアミノ)−6
−モルホリノ−ピリミジンの製造:
2,4−ジアミノ−6−モルホリノピリミジン
5.0gを用い実施例1と同様に反応させて処理する
ことにより、次の物理的性質を有する表記化合物
7.47gを得た。
融点:189〜191℃
IR(KBr):ν=3275,1730,1680,1630,
1575,1540,1495,1440,1285,1255,1230,
1195,1130,1020,930,895cm-1
NMR(CDCl3):δ=8.73(1H,br,s),8.48
(1H,br,s),7.22(1H,s),4.05(2H,s),
3.97(2H,s),3.68(8H,m),3.47(3H,s),
3.45(3H,s)
元素分析値
計算値:C,49.55;H,6.24;
N,20.64(%)
実測値:C,49.62;H,6.20;
N,20.66(%)
実施例 3
2,6−ビス(メトキシアセチルアミノ)ピリ
ジンの製造:
2,6−ジアミノピリジン2.15gをピリジン100
mlに溶かした溶液に、室温で塩化メトキシアセチ
ル3.8mlを滴下後、室温で終夜攪拌した。反応混
合物よりピリジンを減圧溜去して得られた残渣に
水を加え、生成した固体を濾取し、水で洗浄して
粗結晶を得る。これをエタノールより再結晶し、
次の物理的性質を有する表記化合物1.67gを得た。
融点:146〜147℃
IR(KBr):ν=3410,1710,1590,1515,
1460,1420,1310,1245,1200,1120,990,
800,685cm-1
NMR(DMSO−d6):δ=9.50(2H,br,s),
7.75(3H,s),4.05(4H,s),3.37(6H,s)
元素分析値
計算値:C,52.17;H,5.97;
N,16.59(%)
分析値:C,52.24;H,6.03;
N,16.74(%)
実施例 4
2,4−ビス(メトキシアセチルアミノ)−6
−フエニル−syn−トリアジン
2,4−ジアミノ−6−フエニル−syn−トリ
アジン5.6gをピリジン80mlに溶かし、室温で塩化
メトキシアセチル6.0mlを滴下後、80℃に加熱し、
1.5時間攪拌した。反応混合物よりピリジンを減
圧溜去して得られた残渣に水及びクロロホルムを
加えて分液した。有機層を芒硝で乾燥し、溶媒を
減圧溜去して粗結晶を得る。これをエタノールよ
り再結晶して次の物理的性質を有する表記化合物
4.9gを得た。
融点 171〜173℃(分解)
IR(KBr):ν=3450,3260,1760,1700,
1595,1550,1530,1500,1475,1415,1380,
1335,1255,1200,1125,1075,1055,990,
830,785cm-1
NMR(DMSO−d6):δ=11.71(2H,br,s),
8.42〜8.15(2H),7.75〜7.25(3H),4.44(4H,
s),3.34(6H,s)
元素分析値
計算値:C,54.38;H,5.17;
N,21.14(%)
実測値:C,54.62;H,5.26;
N,21.15(%)
実施例 5
2,4−ビス(アセトキシアセチルアミノ)−
6−ピペリジノピリミジンの製造:
2,4−ジアミノ−6−ピペリジノピリミジン
9.66gをピリジン200mlに溶かした溶液に室温で塩
化アセトキシアセチル12mlを滴下した。終夜室温
で攪拌した後、反応混合物よりピリジンを減圧溜
去して得られた固体を水、次いでクロロホルムで
洗浄して粗結晶を得た。これをジオキサンより再
結晶して次の物理的性質を有する表記化合物
4.87gを得た。
融点:248〜249℃(分解)
IR(KBr):ν=3450,3230,3030,2940,
1760,1690,1640,1580,1530,1450,1410,
1220,1200,1080,810cm-1
NMR(DMSO−d6):δ=10.30(1H,s),
10.00(1H,s),7.00(1H,s),5.00(2H,s),
4.72(2H,s),3.55(4H,br.s),2.10(6H,s),
1.60(6H,br.s)
元素分析値
計算値:C,51.90;H,5.89;
N,17.80(%)
実測値:C,51.75;H,5.97;
N,17.73(%)
実施例 6
2,4−ビス(ヒドロキシアセチルアミノ)−
6−ピペリジノピリミジンの製造:
実施例5により製造される2,4−ビス(アセ
トキシアセチルアミノ)−6−ピペリジノピリミ
ジン7.02gに15%アンモニアメタノール溶液150ml
を加え、50〜60℃で4時間加熱還流した。放冷後
固体を濾取し、メタノールで洗浄して次の物理的
性質を有する表記化合物4.93gを得た。
融点:196〜198℃
IR(KBr):ν=3400,3300,1735,1680,
1620,1565,1540,1480,1455,1380,1310,
1240,1215,1105,785cm-1
NMR(DMSO−d6):δ=7.07(1H,s),4.13
(2H,s),4.00(2H,s),3.52(4H,br.s),
3.48(2H,s),1.57(6H,br.s)
元素分析値
計算値:C,50.48;H,6.19;
N,22.64(%)
実測値:C,50.52;H,6.24;
N,22.50(%)
実施例 7
4.6−ビス(メトキシアセチルアミノ)ピリミ
ジンの製造:
4.6−ジアミノピリミジン・1/2硫酸塩4.8gをピ
リジン80mlに溶かした溶液に室温で塩化メトキシ
アセチル6.0mlを滴下した。その後室温で16時間、
次いで80℃で1時間攪拌した。放冷後、析出する
結晶を濾過により除き、濾液よりピリジンを減圧
溜去した。残渣に水およびクロロホルムを加え分
液した。有機層を水および飽和食塩水で洗浄した
後、芒硝で乾燥した。
溶媒を減圧除去して粗結晶を得た。これを酢酸
エチル−ヘキサンより再結晶して次の物理的性質
を有する表記化合物2.9gを得た。
融点:110〜112℃
IR(KBr):ν=3380,3160,2960,2910,
2840,1720,1570,1505,1490,1430,1410,
1365,1310,1270,1255,1200,1160,1110,
1010,985,880,830,775,680,590,555cm-1
NMR(DMSO−d6):δ=10.28(2H,br.s),
8.73(1H,s),8.53(1H,s),4.06(4H,s),
3.34(6H,s)
元素分析値
計算値:C,47.24;H,5.55:
N,22.04(%)
実測値:C,47.53;H,5.55;
N,22.14(%)
実施例 8
2,4−ビス(メトキシアセチルアミノ)ピリ
ミジンの製造:
2,4−ジアミノピリミジン4.4gをピリジン
100mlに溶かした溶液に室温で塩化メトキシアセ
チル8.0mlを滴下する。その後室温で2時間攪拌
した。析出した結晶を濾過により除き濾液よりピ
リジンを減圧溜去して得た残渣に水およびクロロ
ホルムを加え分液した。有機層を水、ついで飽和
食塩水で洗浄した後、芒硝で乾燥した。溶媒を減
圧溜去して粗結晶を得た。これをエタノールより
再結晶して次の物理的性質を有する表記化合物
4.7gを得た。
融点:168〜170℃(分解)
IR(KBr):ν=3480,3420,3320,3200,
3070,3030,2940,2840,1735,1690,1600,
1560,1505,1455,1420,1355,1340,1325,
1285,1215,1195,1120,1015,995,990,940,
850,825,795,755,690,620cm-1
NMR(DMSO−d6):δ=10.29(1H,br.s),
10.09(1H,br.s),8.49(1H,d),7.18(1H,
d),4.22(2H,s),4.12(2H,s),3.35(3H,
s),3.32(3H,s)
元素分析値
計算値:C,47.24;H,5.55:
N,22.04(%)
実測値:C,47.01;H,5.34;
N,21.77(%)
実施例 9
2,4−ビス(メトキシアセチルアミノ)−6
−メトキシピリミジンの製造:
2,4−ジアミノ−6−メトキシピリミジン
3.8gをピリジン80mlに溶かした溶液に室温で塩化
メトキシアセチル6.0mlを滴下した。室温で2時
間攪拌した後、ピリジンを減圧溜去した。得られ
た残渣に水およびクロロホルムを加えて分液し
た。有機層を水、次いで飽和食塩水で洗浄した
後、芒硝で乾燥した。溶媒を減圧溜去して粗結晶
を得た。これをエタノールより再結晶して次の物
理的性質を有する表記化合物3.8gを得た。
融点:168〜169℃
IR(KBr)ν=3400,3270,3190,3010,
2940,2830,1735,1690,1625,1585,1550,
1535,1490,1435,1420,1390,1340,1280,
1260,1205,1185,1130,1095,1040,995,
960,935,840,795,780,750,630cm-1
NMR(DMSO−d6):δ=10.02(2H,br.s),
7.05(1H,s),4.26(2H,s),4.06(2H,s),
3.87(3H,s),3.34(6H,s)
元素分析値
計算値:C,46.48;H,5.67:
N,19.71(%)
実測値:C,46.69;H,5.72;
N,19.98(%)
実施例 10
2,6−ビス(メトキシアセチルアミノ)−4
−クロロピリミジンの製造:
4−クロロ−2,6−ジアミノピリミジン5.8g
をピリジン100mlに溶かした溶液に室温で塩化メ
トキシアセチル8.0mlを滴下した。室温で2時間
攪拌した後、反応混合物よりピリジンを減圧溜去
した。得られた残渣に水およびクロロホルムを加
えて分液した。有機層を水、次いで飽和食塩水で
洗浄した後、芒硝で乾燥した。溶媒を減圧溜去し
て粗結晶を得た。これを酢酸エチル−ヘキサンよ
り再結晶して次の物理的性質を有する表記化合物
3.2gを得た。
融点:142〜144℃(分解)
IR(KBr):ν=3450,3270,1735,1695,
1580,1540,1500,1430,1410,1355,1330,
1270,1205,1125,1040,985,955,930,840cm
−1
NMR(DMSO−d6):δ=10.62(1H,br.s),
10.42(1H,br.s),7.69(1H,s),4.21(2H,
s),4.12(2H,s),3.32(6H,s)
元素分析値
計算値:C,41.61;H,4.54:
N,19.41;Cl,12.28
(%)
実測値:C,41.34;H,4.36;
N,19.79;Cl,12.55
(%)
実施例 11
2,4−ビス(エトキシアセチルアミノ)−6
−ピペリジノピリミジンの製造:
2,4−ジアミノ−6−ピペリジノピリミジン
5.61gをピリジン100mlに溶かした溶液に室温で塩
化エトキシアセチル7mlを滴下した。終夜、室温
で攪拌した後、反応混合物よりピリジンを減圧溜
去した。この残渣に水を加え生成した固体を濾取
した。この固体をクロロホルムに溶かした溶液を
水で洗浄し、芒硝で乾燥した。溶媒を溜去して得
た粗結晶をエタノール−水より再結晶して次の物
理的性質を有する表記化合物8.31を得た。
融点:146〜148℃
IR(KBr):ν=3250,2930,1720,1680,
1625,1575,1545,1515,1440,1340,1315,
1285,1255,1240,1215,1140,800cm-1
NMR(CDCl3):δ=8.72(1H,br.s),8.48
(1H,br.s),7.22(1H,s),4.10(2H,s),
4.00(2H,s),3.62(2H,q),3.58(2H,q),
3.55(4H,br.s),1.62(6H,br.s),1.30(3H,
t),1.28(3H,t)
元素分析値
計算値:C,55.87;H,7.45:
N,19.17(%)
分析値:C,55.99;H,7.52;
N,19.22(%)
実施例 12
2,4−ビス(2−メトキシエトキシアセチル
アミノ)−6−ピペリジノピリミジンの製造:
2,4−ジアミノ−6−ピペリジノピリミジン
5.6gをピリジン100mlに溶かした溶液に室温で塩
化2−メトキシエトキシアセチル8.0mlを滴下し
た。65〜70℃で1時間加熱攪拌した後、終夜室温
で放置した。反応混合物よりピリジンを減圧溜去
して得た残渣に水を加えて生成した結晶を濾取し
て、次の物理的性質を有する表記化合物3.54gを
得た。
融点:118〜121℃
IR(KBr):ν=3460,3270,2930,1720,
1680,1625,1580,1545,1520,1440,1315,
1260,1240,1220,1150,1125,805cm-1
NMR(DMSO−d6):δ=9.50(1H,br.s),
9.40(1H,br.s),7.08(1H,s),4.22(2H,s),
4.10(2H,s),3.80〜3.30(12H,m),3.27(3H,
s),3.25(3H,s),1.56(6H,br.s)
元素分析値
計算値:C,53.63;H,7.34:
N,16.46(%)
実測値:C,53.49;H,7.37;
N,16.76(%)[Table] The compounds of the present invention may be administered orally, parenterally or by inhalation, with oral administration being preferred. For use, they are prepared into various formulations by conventional methods using conventional pharmaceutical carriers. For example, tablets, capsules, granules, syrups, powders and the like can be used for oral administration. Examples for parenteral administration include aqueous solutions for intravenous injection, oily suspensions for intramuscular injection, and the like. It can also be administered by an aerosol spray or by an inhaler which provides direct contact of the lungs with the compound of the invention in the form of a dry powder. The total daily dose of the compounds of the invention is between 2 and 2000 mg. EXAMPLES Next, the present invention will be explained in more detail with reference to Examples, but the present invention is not limited thereto. Example 1 2,4-bis(methoxyacetylamino)-6
-Production of piperidino-pyrimidine: 2,4-diamino-6-piperidinopyrimidine
To a solution of 5.0 g dissolved in 100 ml of pyridine, 5 ml of methoxyacetyl chloride was added dropwise at room temperature. after that,
The mixture was stirred at a bath temperature of 60° C. for 1 hour and at room temperature overnight. Pyridine was distilled off under reduced pressure from the reaction mixture, and the resulting solid was suspended in water. The white crystals were collected by filtration and washed with water to obtain 6.27 g of the title compound having the following physical properties. Obtained. Melting point: 159-160℃ IR (KBr): ν=3450, 3260, 2930, 1725,
1685, 1625, 1575, 1520, 1440, 1395, 1340,
1315, 1285, 1260, 1240, 1220, 1205, 1135,
985, 940, 800 cm -1 NMR (DMSO-d 6 ): δ = 9.55 (1H, s), 9.48
(1H, s), 7.05 (1H, s), 4.20 (2H, s), 4.05
(2H, s), 3.53 (4H, br.s), 3.35 (3H, s),
3.32 (3H, s), 1.60 (6H, br.s) Elemental analysis value Calculated value: C, 53.40; H, 6.87; N, 20.76 (%) Actual value: C, 53.46; H, 6.72; N, 20.81 ( %) Example 2 2,4-bis(methoxyacetylamino)-6
-Production of morpholino-pyrimidine: 2,4-diamino-6-morpholinopyrimidine
By reacting and treating 5.0g in the same manner as in Example 1, the title compound having the following physical properties was obtained.
Obtained 7.47g. Melting point: 189-191℃ IR (KBr): ν=3275, 1730, 1680, 1630,
1575, 1540, 1495, 1440, 1285, 1255, 1230,
1195, 1130, 1020, 930, 895 cm -1 NMR (CDCl 3 ): δ = 8.73 (1H, br, s), 8.48
(1H, br, s), 7.22 (1H, s), 4.05 (2H, s),
3.97 (2H, s), 3.68 (8H, m), 3.47 (3H, s),
3.45 (3H, s) Elemental analysis value Calculated value: C, 49.55; H, 6.24; N, 20.64 (%) Actual value: C, 49.62; H, 6.20; N, 20.66 (%) Example 3 2,6- Production of bis(methoxyacetylamino)pyridine: 2.15 g of 2,6-diaminopyridine to 100 g of pyridine
ml of methoxyacetyl chloride was added dropwise to the solution at room temperature, and the mixture was stirred overnight at room temperature. Water is added to the residue obtained by distilling pyridine from the reaction mixture under reduced pressure, and the resulting solid is collected by filtration and washed with water to obtain crude crystals. This was recrystallized from ethanol,
1.67 g of the title compound was obtained with the following physical properties. Melting point: 146-147℃ IR (KBr): ν=3410, 1710, 1590, 1515,
1460, 1420, 1310, 1245, 1200, 1120, 990,
800, 685 cm -1 NMR (DMSO-d 6 ): δ = 9.50 (2H, br, s),
7.75 (3H, s), 4.05 (4H, s), 3.37 (6H, s) Elemental analysis value Calculated value: C, 52.17; H, 5.97; N, 16.59 (%) Analysis value: C, 52.24; H, 6.03 ; N, 16.74 (%) Example 4 2,4-bis(methoxyacetylamino)-6
-Phenyl-syn-triazine 5.6 g of 2,4-diamino-6-phenyl-syn-triazine was dissolved in 80 ml of pyridine, 6.0 ml of methoxyacetyl chloride was added dropwise at room temperature, and the mixture was heated to 80°C.
Stirred for 1.5 hours. Pyridine was distilled off from the reaction mixture under reduced pressure, and water and chloroform were added to the resulting residue to separate the layers. The organic layer was dried with Glauber's salt, and the solvent was distilled off under reduced pressure to obtain crude crystals. Recrystallize this from ethanol to obtain the indicated compound with the following physical properties.
Obtained 4.9g. Melting point 171-173℃ (decomposition) IR (KBr): ν=3450, 3260, 1760, 1700,
1595, 1550, 1530, 1500, 1475, 1415, 1380,
1335, 1255, 1200, 1125, 1075, 1055, 990,
830, 785 cm -1 NMR (DMSO-d 6 ): δ = 11.71 (2H, br, s),
8.42~8.15 (2H), 7.75~7.25 (3H), 4.44 (4H,
s), 3.34 (6H, s) Elemental analysis value Calculated value: C, 54.38; H, 5.17; N, 21.14 (%) Actual value: C, 54.62; H, 5.26; N, 21.15 (%) Example 5 2 ,4-bis(acetoxyacetylamino)-
Production of 6-piperidinopyrimidine: 2,4-diamino-6-piperidinopyrimidine
12 ml of acetoxyacetyl chloride was added dropwise to a solution of 9.66 g dissolved in 200 ml of pyridine at room temperature. After stirring at room temperature overnight, pyridine was distilled off from the reaction mixture under reduced pressure, and the resulting solid was washed with water and then with chloroform to obtain crude crystals. Recrystallize this from dioxane to obtain the indicated compound with the following physical properties.
Obtained 4.87g. Melting point: 248-249℃ (decomposition) IR (KBr): ν=3450, 3230, 3030, 2940,
1760, 1690, 1640, 1580, 1530, 1450, 1410,
1220, 1200, 1080, 810 cm -1 NMR (DMSO-d 6 ): δ = 10.30 (1H, s),
10.00 (1H, s), 7.00 (1H, s), 5.00 (2H, s),
4.72 (2H, s), 3.55 (4H, br.s), 2.10 (6H, s),
1.60 (6H, br.s) Elemental analysis value Calculated value: C, 51.90; H, 5.89; N, 17.80 (%) Actual value: C, 51.75; H, 5.97; N, 17.73 (%) Example 6 2, 4-bis(hydroxyacetylamino)-
Preparation of 6-piperidinopyrimidine: Add 7.02 g of 2,4-bis(acetoxyacetylamino)-6-piperidinopyrimidine prepared according to Example 5 to 150 ml of a 15% ammonia methanol solution.
was added and heated under reflux at 50 to 60°C for 4 hours. After cooling, the solid was collected by filtration and washed with methanol to obtain 4.93 g of the title compound having the following physical properties. Melting point: 196-198℃ IR (KBr): ν=3400, 3300, 1735, 1680,
1620, 1565, 1540, 1480, 1455, 1380, 1310,
1240, 1215, 1105, 785 cm -1 NMR (DMSO-d 6 ): δ = 7.07 (1H, s), 4.13
(2H, s), 4.00 (2H, s), 3.52 (4H, br.s),
3.48 (2H, s), 1.57 (6H, br.s) Elemental analysis value Calculated value: C, 50.48; H, 6.19; N, 22.64 (%) Actual value: C, 50.52; H, 6.24; N, 22.50 ( %) Example 7 Production of 4.6-bis(methoxyacetylamino)pyrimidine: To a solution of 4.8 g of 4.6-diaminopyrimidine 1/2 sulfate dissolved in 80 ml of pyridine, 6.0 ml of methoxyacetyl chloride was added dropwise at room temperature. Then at room temperature for 16 hours.
The mixture was then stirred at 80°C for 1 hour. After cooling, precipitated crystals were removed by filtration, and pyridine was distilled off from the filtrate under reduced pressure. Water and chloroform were added to the residue to separate the layers. The organic layer was washed with water and saturated brine, and then dried over Glauber's salt. The solvent was removed under reduced pressure to obtain crude crystals. This was recrystallized from ethyl acetate-hexane to obtain 2.9 g of the title compound having the following physical properties. Melting point: 110-112℃ IR (KBr): ν=3380, 3160, 2960, 2910,
2840, 1720, 1570, 1505, 1490, 1430, 1410,
1365, 1310, 1270, 1255, 1200, 1160, 1110,
1010, 985, 880, 830, 775, 680, 590, 555 cm -1 NMR (DMSO-d 6 ): δ = 10.28 (2H, br.s),
8.73 (1H, s), 8.53 (1H, s), 4.06 (4H, s),
3.34 (6H, s) Elemental analysis value Calculated value: C, 47.24; H, 5.55: N, 22.04 (%) Actual value: C, 47.53; H, 5.55; N, 22.14 (%) Example 8 2,4- Production of bis(methoxyacetylamino)pyrimidine: 4.4g of 2,4-diaminopyrimidine was added to pyridine.
Add 8.0 ml of methoxyacetyl chloride dropwise to the 100 ml solution at room temperature. Thereafter, the mixture was stirred at room temperature for 2 hours. The precipitated crystals were removed by filtration, and the pyridine was distilled off under reduced pressure from the filtrate. Water and chloroform were added to the resulting residue to separate the layers. The organic layer was washed with water and then with saturated brine, and then dried over Glauber's salt. The solvent was distilled off under reduced pressure to obtain crude crystals. Recrystallize this from ethanol to obtain the indicated compound with the following physical properties.
Obtained 4.7g. Melting point: 168-170℃ (decomposition) IR (KBr): ν=3480, 3420, 3320, 3200,
3070, 3030, 2940, 2840, 1735, 1690, 1600,
1560, 1505, 1455, 1420, 1355, 1340, 1325,
1285, 1215, 1195, 1120, 1015, 995, 990, 940,
850, 825, 795, 755, 690, 620 cm -1 NMR (DMSO-d 6 ): δ = 10.29 (1H, br.s),
10.09 (1H, br.s), 8.49 (1H, d), 7.18 (1H,
d), 4.22 (2H, s), 4.12 (2H, s), 3.35 (3H,
s), 3.32 (3H, s) Elemental analysis value Calculated value: C, 47.24; H, 5.55: N, 22.04 (%) Actual value: C, 47.01; H, 5.34; N, 21.77 (%) Example 9 2 ,4-bis(methoxyacetylamino)-6
-Production of methoxypyrimidine: 2,4-diamino-6-methoxypyrimidine
6.0 ml of methoxyacetyl chloride was added dropwise to a solution of 3.8 g dissolved in 80 ml of pyridine at room temperature. After stirring at room temperature for 2 hours, pyridine was distilled off under reduced pressure. Water and chloroform were added to the obtained residue to separate the layers. The organic layer was washed with water and then with saturated brine, and then dried over Glauber's salt. The solvent was distilled off under reduced pressure to obtain crude crystals. This was recrystallized from ethanol to obtain 3.8 g of the title compound having the following physical properties. Melting point: 168-169℃ IR (KBr) ν = 3400, 3270, 3190, 3010,
2940, 2830, 1735, 1690, 1625, 1585, 1550,
1535, 1490, 1435, 1420, 1390, 1340, 1280,
1260, 1205, 1185, 1130, 1095, 1040, 995,
960, 935, 840, 795, 780, 750, 630 cm -1 NMR (DMSO-d 6 ): δ = 10.02 (2H, br.s),
7.05 (1H, s), 4.26 (2H, s), 4.06 (2H, s),
3.87 (3H, s), 3.34 (6H, s) Elemental analysis value Calculated value: C, 46.48; H, 5.67: N, 19.71 (%) Actual value: C, 46.69; H, 5.72; N, 19.98 (%) Example 10 2,6-bis(methoxyacetylamino)-4
-Manufacture of chloropyrimidine: 5.8g of 4-chloro-2,6-diaminopyrimidine
8.0 ml of methoxyacetyl chloride was added dropwise to a solution of 100 ml of pyridine at room temperature. After stirring at room temperature for 2 hours, pyridine was distilled off from the reaction mixture under reduced pressure. Water and chloroform were added to the obtained residue to separate the layers. The organic layer was washed with water and then with saturated brine, and then dried over Glauber's salt. The solvent was distilled off under reduced pressure to obtain crude crystals. This was recrystallized from ethyl acetate-hexane to obtain the indicated compound with the following physical properties.
Obtained 3.2g. Melting point: 142-144℃ (decomposition) IR (KBr): ν=3450, 3270, 1735, 1695,
1580, 1540, 1500, 1430, 1410, 1355, 1330,
1270, 1205, 1125, 1040, 985, 955, 930, 840cm
−1 NMR (DMSO−d 6 ): δ=10.62 (1H, br.s),
10.42 (1H, br.s), 7.69 (1H, s), 4.21 (2H,
s), 4.12 (2H, s), 3.32 (6H, s) Elemental analysis value Calculated value: C, 41.61; H, 4.54: N, 19.41; Cl, 12.28 (%) Actual value: C, 41.34; H, 4.36 ; N, 19.79; Cl, 12.55 (%) Example 11 2,4-bis(ethoxyacetylamino)-6
-Production of piperidinopyrimidine: 2,4-diamino-6-piperidinopyrimidine
7 ml of ethoxyacetyl chloride was added dropwise to a solution of 5.61 g dissolved in 100 ml of pyridine at room temperature. After stirring at room temperature overnight, pyridine was distilled off from the reaction mixture under reduced pressure. Water was added to this residue and the resulting solid was collected by filtration. A solution of this solid in chloroform was washed with water and dried with Glauber's salt. The crude crystals obtained by distilling off the solvent were recrystallized from ethanol-water to obtain the title compound 8.31 having the following physical properties. Melting point: 146-148℃ IR (KBr): ν=3250, 2930, 1720, 1680,
1625, 1575, 1545, 1515, 1440, 1340, 1315,
1285, 1255, 1240, 1215, 1140, 800cm -1 NMR (CDCl 3 ): δ = 8.72 (1H, br.s), 8.48
(1H, br.s), 7.22 (1H, s), 4.10 (2H, s),
4.00 (2H, s), 3.62 (2H, q), 3.58 (2H, q),
3.55 (4H, br.s), 1.62 (6H, br.s), 1.30 (3H,
t), 1.28 (3H, t) Elemental analysis value Calculated value: C, 55.87; H, 7.45: N, 19.17 (%) Analysis value: C, 55.99; H, 7.52; N, 19.22 (%) Example 12 2 , 4-bis(2-methoxyethoxyacetylamino)-6-piperidinopyrimidine: 2,4-diamino-6-piperidinopyrimidine
8.0 ml of 2-methoxyethoxyacetyl chloride was added dropwise to a solution of 5.6 g dissolved in 100 ml of pyridine at room temperature. After heating and stirring at 65 to 70°C for 1 hour, the mixture was left at room temperature overnight. Pyridine was distilled off from the reaction mixture under reduced pressure, water was added to the residue, and the resulting crystals were collected by filtration to obtain 3.54 g of the title compound having the following physical properties. Melting point: 118-121℃ IR (KBr): ν=3460, 3270, 2930, 1720,
1680, 1625, 1580, 1545, 1520, 1440, 1315,
1260, 1240, 1220, 1150, 1125, 805cm -1 NMR (DMSO-d 6 ): δ = 9.50 (1H, br.s),
9.40 (1H, br.s), 7.08 (1H, s), 4.22 (2H, s),
4.10 (2H, s), 3.80~3.30 (12H, m), 3.27 (3H,
s), 3.25 (3H, s), 1.56 (6H, br.s) Elemental analysis value Calculated value: C, 53.63; H, 7.34: N, 16.46 (%) Actual value: C, 53.49; H, 7.37; N ,16.76(%)
Claims (1)
セチル基またはアルコキシアルキル基;R2は水
素原子、塩素原子、フエニル基、低級アルコキシ
基または【式】(R3およびR4は炭 素数1〜3のアルキレン基、Wは酸素原子または
メチレン基)で示される基;X,YおよびZは全
てが同時にCH−であることはなく、それぞれ
窒素原子またはCH−を示す。〕で示される新
規なアミド化合物。[Claims] 1 Formula: [In the formula, R 1 is a hydrogen atom, a lower alkyl group, an acetyl group, or an alkoxyalkyl group; R 2 is a hydrogen atom, a chlorine atom, a phenyl group, a lower alkoxy group, or [ A group represented by formula] (R 3 and R 4 are alkylene groups having 1 to 3 carbon atoms, W is an oxygen atom or a methylene group); X, Y and Z are not all CH- at the same time, and each is a nitrogen Indicates an atom or CH-. ] A novel amide compound represented by
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27658587A JPH01117863A (en) | 1987-10-30 | 1987-10-30 | Novel amide compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27658587A JPH01117863A (en) | 1987-10-30 | 1987-10-30 | Novel amide compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01117863A JPH01117863A (en) | 1989-05-10 |
| JPH0581589B2 true JPH0581589B2 (en) | 1993-11-15 |
Family
ID=17571511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP27658587A Granted JPH01117863A (en) | 1987-10-30 | 1987-10-30 | Novel amide compound |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH01117863A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2766187B1 (en) * | 1997-07-17 | 2000-06-02 | Rhone Poulenc Rorer Sa | PYRAZINE DERIVATIVES, THEIR PREPARATION AND THE MEDICINES CONTAINING THEM |
-
1987
- 1987-10-30 JP JP27658587A patent/JPH01117863A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH01117863A (en) | 1989-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0729457B1 (en) | Diaminocyclobutene-3,4-diones as smooth muscle relaxants | |
| JP4833080B2 (en) | Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, methods for their preparation and their use as inhibitors of FAAH enzymes | |
| US5506252A (en) | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones | |
| JP3939246B2 (en) | Indoloquinazolinones | |
| JP2006525293A (en) | Piperidinyl- and piperazinyl-alkyl carbamate derivatives, their preparation and therapeutic use | |
| WO2008070831A2 (en) | Bisbenzamidines and bisbenzamidoximes for the treatment of human african trypanosomiasis | |
| JP4204980B2 (en) | 9-aminoacridine derivative and method for producing the same | |
| JPS62252780A (en) | Novel indenothiazole derivative and production thereof | |
| FR2556720A1 (en) | DERIVATIVES OF AMIDINE AND TONICARDIACS CONTAINING THEM | |
| WO2004000321A1 (en) | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis | |
| US4912135A (en) | Amide compounds | |
| EP0077534B1 (en) | Benzamide derivatives, a process for preparing the same, and pharmaceutical compositions containing the same | |
| JPH0528701B2 (en) | ||
| JPH0581589B2 (en) | ||
| JP7815213B2 (en) | Benzylamine derivatives, their preparation method and uses | |
| EP2029580B1 (en) | Novel indol-pyrrol derivatives for the treatment of proliferative and inflammatory diseases | |
| CA1219873A (en) | Diazine-ethenyl-phenyl oxamic acids and esters and salts thereof | |
| KR900001885B1 (en) | 5-Chloro-s-triazolo [4, 3-a] pyridine-7-carboxylic acid and preparation method thereof | |
| US5041462A (en) | Novel substituted acetamide compounds and use as anti-allergic agents | |
| WO1994003439A1 (en) | Antiproliferative tricyclic compounds | |
| JPH03294277A (en) | Piperidine derivative | |
| KR970011454B1 (en) | Novel amide compounds | |
| JPH02311450A (en) | Novel benzonitrile derivative | |
| JP2802778B2 (en) | Homopiperazine derivatives and cerebral protective agents containing the same | |
| JPH02311451A (en) | Novel benzonitrile derivative |